FdaApplication
BLA 125104
Identifiers
- fda_app_no: BLA125104
Properties
| Property | Value |
|---|---|
| applicant_name | Biogen Inc. |
| application_type | BLA |
| approval_date | 2004-11-23 |
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| TYSABRI | NATALIZUMAB | 300MG/15ML (20MG/ML) | VIAL;SINGLE-USE |
1 product